Developmentally vitamin D-deficient rats show enhanced prepulse inhibition after acute δ9-tetrahydrocannabinol

Behavioural Pharmacology

Volumn 25, Issue 3, 2014, Pages 236-244

  Burne, Thomas H J ^a,b   Alexander, Suzanne ^a,b   Turner, Karly M ^a   Eyles, Darryl W ^a,b   McGrath, John J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Centre for Mental Health Research   (Australia)

Author keywords

animal model; neurodevelopment; rat; schizophrenia; vitamin D

Indexed keywords

DRONABINOL; VITAMIN D; ANALGESIC AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVELOPMENTAL VITAMIN D DEFICIENCY; LOCOMOTION; MATERNAL NUTRITION; MEMORY; NERVE CELL DIFFERENTIATION; NONHUMAN; OPEN FIELD TEST; POSITIVE SYNDROME; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SENSORY GATING; STARTLE REFLEX; TASK PERFORMANCE; VITAMIN D DEFICIENCY; ANIMAL; AUDITORY STIMULATION; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; SPRAGUE DAWLEY RAT;

ACOUSTIC STIMULATION; ANALGESICS, NON-NARCOTIC; ANIMALS; DISEASE MODELS, ANIMAL; DRONABINOL; EXPLORATORY BEHAVIOR; LOCOMOTION; PREPULSE INHIBITION; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING; VITAMIN D DEFICIENCY;

EID: 84899864705     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000041     Document Type: Article

References (52)

1. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002).Cannabis use in adolescence and risk for adult psychosis: longitudinalprospective study. BMJ 325:1212-1213.
2. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal associationbetween cannabis and psychosis: examination of the evidence. Br JPsychiatry 184:110-117.
3. Becker A, Eyles DW, McGrath JJ, Grecksch G (2005). Transient prenatal vitaminD deficiency is associated with subtle alterations in learning and memoryfunctions in adult rats. Behav Brain Res 161:306-312.
4. Bortolato M, Aru GN, Frau R, Orru M, Luckey GC, Boi G, Gessa GL (2005). TheCB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulseinhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl)177:264-271.
5. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T (2007).Heterozygous neuregulin 1 mice are more sensitive to the behavioural effectsof Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192:325-336.
6. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibitionof startle: normal subjects, patient groups, and pharmacological studies.Psychopharmacology (Berl) 156:234-258.
7. Burne TH, Becker A, Brown J, Eyles DW, Mackay-Sim A, McGrath JJ (2004).Transient prenatal Vitamin D deficiency is associated with hyperlocomotion inadult rats. Behav Brain Res 154:549-555.
8. Carpenter WT Jr, Buchanan RW (1994). Schizophrenia. N Engl J Med 330:681-690.
9. Cui XY, McGrath JJ, Burne THJ, Mackay-Sim A, Eyles DW (2007). Maternalvitamin D depletion alters neurogenesis in the developing rat brain. Int J DevNeurosci 25:227-232.
10. Dudchenko PA, Talpos J, Young J, Baxter MG (2013). Animal models of workingmemory: a review of tasks that might be used in screening drug treatments forthe memory impairments found in schizophrenia. Neurosci Biobehav Rev37:2111-2124.
11. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F (2003). Vitamin D-3 andbrain development. Neuroscience 118:641-653.
12. Eyles D, Burne T, McGrath J (2011). Vitamin D in fetal brain development. SeminCell Dev Biol 22:629-636.
13. Feron F, Burne THJ, Brown J, Smith E, McGrath JJ, Mackay-Sim A, Eyles DW(2005). Developmental vitamin D-3 deficiency alters the adult rat brain. BrainRes Bull 65:141-148.
14. Flagstad P, Glenthoj BY, Didriksen M (2005). Cognitive deficits caused by lategestational disruption of neurogenesis in rats: a preclinical model ofschizophrenia. Neuropsychopharmacology 30:250-260.
15. Gray JA, Feldon J, Rawlins JNP, Smith AD, Hemsley DR (1991). Theneuropsychology of schizophrenia. Behav Brain Sci 14:1-19
16. Green MF (1996). What are the functional consequences of neurocognitivedeficits in schizophrenia? Am J Psychiatry 153:321-330.
17. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008). Gene-environment interplay between cannabis and psychosis. Schizophr Bull34:1111-1121.
18. Heyser CJ, Hampson RE, Deadwyler SA (1993). Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations inshort-term memory associated with changes in task specific firing ofhippocampal cells. J Pharmacol Exp Ther 264:294-307.
19. Hong LE, Wonodi I, Lewis J, Thaker GK (2008). Nicotine effect on prepulseinhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology33:2167-2174.
20. Ilan AB, Smith ME, Gevins A (2004). Effects of marijuana on neurophysiologicalsignals of working and episodic memory. Psychopharmacology (Berl)176:214-222.
21. Kesby JP, Burne TH, McGrath JJ, Eyles DW (2006). Developmental vitamin Ddeficiency alters MK 801-induced hyperlocomotion in the adult rat: an animalmodel of schizophrenia. Biol Psychiatry 60:591-596.
22. Kesby JP, Cui X, Ko P, McGrath JJ, Burne TH, Eyles DW (2009). Developmentalvitamin D deficiency alters dopamine turnover in neonatal rat forebrain.Neurosci Lett 461:155-158.
23. Kesby JP, Cui X, O'Loan J, McGrath JJ, Burne TH, Eyles DW (2010).Developmental vitamin D deficiency alters dopamine-mediated behaviorsand dopamine transporter function in adult female rats. Psychopharmacology(Berl) 208:159-168.
24. Kesby JP, O'Loan JC, Alexander S, Deng C, Huang XF, McGrath JJ, et al. (2012).Developmental vitamin D deficiency alters MK-801-induced behaviours inadult offspring. Psychopharmacology (Berl) 220:455-463.
25. Kesby JP, Cui X, Burne TH, Eyles DW (2013). Altered dopamine ontogeny in thedevelopmentally vitamin D deficient rat and its relevance to schizophrenia.Front Cell Neurosci 7:111.
26. Klug M, van den Buuse M (2013). An investigation into "two hit" effects of BDNFdeficiency and young-adult cannabinoid receptor stimulation on prepulseinhibition regulation and memory in mice. Front Behav Neurosci 7:149.
27. Ko P, Burkert R, McGrath J, Eyles D (2004). Maternal vitamin D-3 deprivation andthe regulation of apoptosis and cell cycle during rat brain development. BrainRes Dev Brain Res 153:61-68.
28. Koch M (1999). The neurobiology of startle. Prog Neurobiol 59:107-128.
29. Kodaira M, Tsuruhara A, Motomura E, Tanii H, Inui K, Kakigi R (2013). Effects ofacute nicotine on prepulse inhibition of auditory change-related corticalresponses. Behav Brain Res 256:27-35.
30. Long LE, Chesworth R, Arnold JC, Karl T (2010a). A follow-up study: acutebehavioural effects of Delta(9)-THC in female heterozygous neuregulin 1transmembrane domain mutant mice. Psychopharmacology (Berl) 211:277-289.
31. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010b). Abehavioural comparison of acute and chronic Delta9-tetrahydrocannabinol andcannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13:861-876.
32. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2013).Transmembrane domain Nrg1 mutant mice show altered susceptibility to theneurobehavioural actions of repeated THC exposure in adolescence. Int JNeuropsychopharmacol 16:163-175.
33. Lubow RE, Gewirtz JC (1995). Latent inhibition in humans-data, theory, andimplications for schizophrenia. Psychol Bull 117:87-103.
34. Mallet PE, Beninger RJ (1998). The cannabinoid CB1 receptor antagonistSR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinolor anandamide. Psychopharmacology (Berl) 140:11-19.
35. Malone DT, Taylor DA (2006). The effect of Delta9-tetrahydrocannabinol onsensorimotor gating in socially isolated rats. Behav Brain Res 166:101-109.
36. Mazzoncini R, Donoghue K, Hart J, Morgan C, Doody GA, Dazzan P, et al. (2010).Illicit substance use and its correlates in first episode psychosis. ActaPsychiatr Scand 121:351-358.
37. McGrath J (1999). Hypothesis: is low prenatal vitamin D a risk-modifying factorfor schizophrenia? Schizophr Res 40:173-177.
38. McGrath J, Saha S, Chant D, Welham J (2008). Schizophrenia: a conciseoverview of incidence, prevalence, and mortality. Epidemiol Rev 30:67-76.
39. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. (2010).Neonatal vitamin D status and risk of schizophrenia: a population-basedcase-control study. Arch Gen Psychiatry 67:889-894.
40. Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, et al. (2006).Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of theprepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav84:330-336.
41. Nuechterlein KH, Robbins TW, Einat H (2005). Distinguishing separable domainsof cognition in human and animal studies: what separations are optimal fortargeting interventions? A summary of recommendations from breakout group2 at the measurement and treatment research to improve cognition inschizophrenia new approaches conference. Schizophr Bull 31:870-874.
42. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia.Arch Gen Psychiatry 52:998-1007.
43. Panlilio LV, Yasar S, Thorndike EB, Goldberg SR, Schindler CW (2011).Automatic recording of mediating behavior in delayed matching- andnonmatching-to-position procedures in rats. Psychopharmacology (Berl)214:495-504.
44. Panlilio LV, Ferre S, Yasar S, Thorndike EB, Schindler CW, Goldberg SR (2012).Combined effects of THC and caffeine on working memory in rats. Br JPharmacol 165:2529-2538.
45. Robbins TW (2005). Synthesizing schizophrenia: a bottom-up, symptomaticapproach. Schizophr Bull 31:854-864.
46. Scholes KE, Martin-Iverson MT (2009). Alterations to pre-pulse inhibition (PPI) inchronic cannabis users are secondary to sustained attention deficits.Psychopharmacology (Berl) 207:469-484.
47. Stanley-Cary CC, Harris C, Martin-Iverson MT (2002). Differing effects of thecannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, onprepulse inhibition of the acoustic startle reflex in the rat. Behav Pharmacol13:15-28.
48. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T,Ghosh S, et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. AmJ Hum Genet 71:877-892.
49. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Sharp R, Auerbach PP(2003). Dopamine agonists disrupt visual latent inhibition in normalmales using a within-subject paradigm. Psychopharmacology (Berl)169:314-320.
50. Toda M, Abi-Dargham A (2007). Dopamine hypothesis of schizophrenia: makingsense of it all. Curr Psychiatry Rep 9:329-336.
51. Turner KM, Young JW, McGrath JJ, Eyles DW, Burne TH (2013). Cognitiveperformance and response inhibition in developmentally vitamin D (DVD)-deficient rats. Behav Brain Res 242:47-53.
52. Vadhan NP, Serper MR, Haney M (2009). Effects of delta-THC on workingmemory: implications for schizophrenia? Prim psychiatry 16:51-99.